|
Ref. | Goal of Study | Results | Pro- or antiangiogenic | Direct or Indirect Effects |
|
[192] | To determine whether PPAR ligands induce EC proliferation or influence cytokine-induced proliferation in vitro. | PPAR ligands troglitazone and pioglitazone negligibly affected basal EC proliferation in vitro; troglitazone and pioglitazone significantly inhibited FGF-2-induced EC growth. | • Antiangiogenic activity as shown by inhibiting FGF-2-induced EC proliferation | Not reported |
|
[22] | To determine effects of PPAR ligands on in vitro and in vivo angiogenesis and EC proliferation. | 15d-PGJ2, BRL49653, or ciglitazone, dose-dependently suppresses HUVEC differentiation into tube-like structures and cell proliferation; 15d-PGJ2 downregulated VEGFR1, VEGFR2 and uPA and increased PAI-1 mRNA expression in vitro; 15d-PGJ2 inhibited angiogenesis in vivo. | • Antiangiogenic activity | Not reported |
• Anti-cell proliferation and anti-cell differentiation activity |
|
[193] | To determine whether human ECs express PPAR and if PPAR regulates PAI-1 expression in EC. | ECs expressed functionally active PPAR; PPAR ligands (15d-PGJ2) and oxidized linoleic acid regulated PAI-1 expression in ECs. | • Antiangiogenic activity by inhibiting fibrinolysis (fibrin induces angiogenesis) | Not reported |
|
[194] | To determine the antiangiogenic effects of PPAR agonists on CNV in vitro and on experimental laser photocoagulation-induced CNV in vivo. | PPAR ligands troglitazone and rosiglitazone inhibited VEGF-induced migration and proliferation of human RPE cells and bovine CECs and tube formation of CEC in a dose-response manner; troglitazone inhibited CNV in rat and monkey eyes. | • Antiangiogenic activity in the eye | Not reported |
• Anti-cell proliferation activity |
|
[195] | To determine whether PPAR ligands inhibit cancer cell growth and cancer-associated angiogenesis. | PPAR expressed in tumor EC; rosiglitazone suppressed primary tumor growth and metastasis; rosiglitazone inhibited bovine capillary EC but not tumor cell proliferation; rosiglitazone decreased VEGF production by tumor cells in vitro; rosiglitazone suppressed angiogenesis in vivo and in a variety of primary tumors. | • Antiangiogenic activity | Direct and indirect |
• Anti-EC but not tumor cell proliferation activity |
|
[196] | To determine whether PPAR ligands regulate PPAR and CD36 gene expression in microvascular and large vessel EC in vitro and modulate TSP-1 peptide ABT510 antiangiogenic activity in tumor-associated endothelium in vivo (mouse tumor models). | 15d-PGJ2, troglitazone, and rosiglitazone induced PPAR and CD36 gene expression in EC in vitro and inhibited angiogenic endothelial functions in vitro and neovascularization in vivo in an additive manner; ABT510 and PPAR ligands enhancedsynergistically the antiangiogenic and antitumor effects of TSP-1 peptide ABT510. | • Antiangiogenic activity | Direct for in vitro activities |
• Anti-proliferation activity in EC |
• Anti-invasion activity of EC |
• Cooperative inhibition of EC angiogenic functions |
• Synergistic inhibition of tumor angiogenesis |
[197] | To determine whether PPAR agonists modulate bone marrow-derived bipotential APCs to promote endothelial lineage differentiation and re-endothelialization after vascular intervention. | Rosiglitazone promoted differentiation of bone marrow-derived APCs toward the endothelial lineage and attenuated restenosis after angioplasty in C57/BL6 mice; rosiglitazone inhibited APC differentiation toward smooth muscle cell lineage. | • Proangiogenic activity | Not reported |
• Anti-inflammatory |
• Promoted lineage-specific differentiation |
|
[198] | To determine the efficacy of pioglitazone to inhibit corneal neovascularization. | PPAR ligand pioglitazone decreased MVD in a VEGF-induced neovascularization in a rat cornea model. | • Antiangiogenic activity in the eye | Not reported |
|
[24] | To determine whether PPAR ligands can inhibit angiogenesis in A549 lung cancer cell xenograft in vivo and which signaling pathway is involved in vitro. | PPAR ligands troglitazone and pioglitazone significantly inhibited A549 primary tumor growth in SCID mice, likely due to inhibition of cancer-associated angiogenesis; in vitro studies on A549 cells suggested PPAR ligands inhibit chemokine expression and inhibit NF-κB activity, the transcription factor necessary for chemokine expression. | • Antiangiogenic activity | Direct and indirect |
• Inhibited NF-κB transcription factor activity |
|
[199] | To determine effects of PPAR ligands on VEGF expression by human endometrial cells. | PPAR ligands rosiglitazone and 15d-PGJ2 repressed VEGF gene expression through a PPRE in the VEGF promoter. | • Antiangiogenic activity | Not reported |
• Identified PPRE in VEGF promoter |
|
[200] | Because endothelial precursor cell (EPC) function is impaired in type 2 diabetic patients and EC dysfunction can be ameliorated by treatment with TZDs, this study asked whether TZDs affect the number and function of EPCs. | Rosiglitazone improved number and migratory activity of EPCs from type 2 diabetic patients; rosiglitazone increased the CD133+ subpopulation of CD34+ cells (stem cells); rosiglitazone increased circulating levels of VEGF; effects may be due to increased bioavailability of NO by Akt-dependent phosphorylation of eNOS—a pathway that is activated by VEGF or the insulin signaling cascade. | • Proangiogenic activity | Not reported |
• Akt survival pathway activated |
• Elevated CD133+/CD34+ stem cells towards EC lineage (VE-cadherin+ and CD31+) |
|
[201] | To determine whether TZDs increase the number of bone marrow-derived EPCs in mice and the signaling pathways activated. | Treatment of mice with pioglitazone upregulated bone marrow and circulating EPCs; pioglitazone prevented apoptosis of human and mouse EPCs in a PI3K-dependent manner in vitro. | • Proangiogenic activity | Not reported; indirect activation of PI3K-Akt not activated by pioglitazone |
• PI3K activated |
• Anti-apoptotic |
|
[27] | To study the effect of PPAR agonists on VEGF- and FGF-2-induced angiogenesis and EC migration. | Pioglitazone and rosiglitazone inhibited the proangiogenic effects of FGF-2 and VEGF in the chick chorioallantoic membrane model angiogenesis; pioglitazone and rosiglitazone inhibited VEGF- and FGF-2-induced EC migration. | • Antiangiogenic in vivo | not reported |
• Inhibited EC migration |
|
[28] | To determine whether activation of PPARα and PPAR stimulates angiogenesis. | PPAR agonist WY14643 and PPAR agonist GW1929 induced EC tube formation in EC/interstitial cell cocultures by increasing VEGF production; WY14643 and GW1929 induced angiogenesis in murine corneal angiogenesis model and Akt activated in vitro. | • Proangiogenic activity | Direct for both PPAR and PPAR |
• Induced VEGF production |
• Prosurvival |
[30] | To investigate the impact of diabetes on ischemia-induced collateral vessel growth, and tested the hypothesis that PPAR agonists augment collateral flow to ischemic tissue. | Pioglitazone ameliorated endothelial dysfunction and enhanced blood flow recovery after tissue ischemia in diabetic mice; pioglitazone restored VEGF levels that were reduced by ischemic injury; Activation of eNOS essential for pioglitazone to promote angiogenesis in ischemic tissue. | • Proangiogenic activity | Not reported |
• Induced VEGF production |
|
[202] | To determine effects of rosiglitazone on gastric cancer cell cycle, proliferation, migration, and invasion; endothelial capillary tube formation (an in vitro measure of angiogenesis). | Rosiglitazone inhibited gastric cancer cell growth, caused G1 cell cycle arrest and induced apoptosis in a dose-dependent and PPAR-dependent manner; rosiglitazone inhibited gastric cancer cell migration, invasion, and expression of MMP-2 in a dose-dependent manner in a PPAR-independent manner; rosiglitazone reduced VEGF-induced “angiogenesis” of HUVEC in a dose- and PPAR-dependent manner. | • Antiangiogenic activity | Not reported |
• Antitumor cell proliferation activity |
• Anti-invasion |
• Proapoptotic |
|
[32] | To determine the effects of PPAR ligands on pancreatic cancer-associated angiogenesis, VEGF expression, and tumor growth in vitro and in vivo. | Rosiglitazone inhibited pancreatic carcinoma growth both in vitro and in vivo; rosiglitazone suppressed xenograft tumor angiogenesis by downregulating VEGF expression; 15d-PGJ2, 9-cis-RA, and their combination inhibited VEGF mRNA expression in PANC-1 cells in a dose- and time-dependent manner; MVD was decreased in rosiglitazone-treated mice. | • Antiangiogenic activity | Not reported |
• Antitumor cell proliferation activity |
|
[203] | To determine whether adipose tissue angiogenesis was stimulated by rosiglitazone using an assay to study angiogenic sprout formation ex vivo. | Obesity and TZD treatment in vivo induced angiogenic sprout formation from adipose tissue fragments, but not from aorta rings; rosiglitazone induced expression of VEGF-A, VEGF-B, and ANGPTL4; ANGPTL4 stimulated EC growth and capillary tube formation; ANGPTL4 alleviated the growth inhibitory actions of rosiglitazone on ECs in the presence or absence of VEGF likely causing a net expansion of the capillary network in adipose tissue in response to PPAR activators. | • Proangiogenic activity in adipose tissue | Indirect likely via a PPAR-stimulated adipocyte-specific factor ANGPLT4 capable of overcoming direct antiangiogenic effect of rosiglitazone on ECs |
• Induced VEGF production |
• Induced ANGPLT4 expression |
|